文献速递心力衰竭与心肌病瓣膜病与结构性心脏病心律失常

梗阻性肥厚型心肌病室间隔减容术后的长期结局:SHARE注册研究

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry.
PubMed 文献 · Circulation · 2024-10-02

基于国际SHARE注册中1832例接受室间隔减容术的梗阻性肥厚型心肌病患者,术后30天死亡率为0.4%,1年时92%的患者左室流出道最大压差<50 mmHg。中位随访6.8年期间,HCM相关死亡年发生率为0.6%,心衰复合结局为1.9%/年,室性心律失常复合结局为0.7%/年。高龄、女性和儿童期手术与心衰发生风险升高相关。

要点

  • 经验丰富的多学科中心行室间隔减容术,短期和长期流出道梗阻缓解均良好。
  • 术后10年无事件生存率为83%,室性心律失常罕见,但部分患者仍进展为心衰。
  • 高龄、女性及儿童期接受手术与心衰复合结局风险升高相关。

核心结论

  • 在经验丰富的多学科HCM中心,室间隔减容术可成功实现短期和长期流出道梗阻缓解,10年无事件生存率为83%,室性心律失常罕见,但部分患者仍进展为心衰。

研究设计与样本

  • 从室间隔减容术时开始随访至末次随访或发生心衰复合结局、室性心律失常复合结局或HCM相关死亡,采用Cox比例风险模型识别结局预测因素。

主要发现

  • 围术期30天死亡率为0.4%(8/1832),1年时1499/1565例(92%)左室流出道最大压差<50 mmHg。
  • 在成人多变量模型中,手术时年龄较大与HCM死亡风险升高相关(风险比1.22 [95%CI 1.1-1.3];P<0.01),每增加5岁与心衰复合结局风险升高相关(风险比1.14 [95%CI 1.1-1.2];P<0.01)。
  • 女性患者术后心衰复合结局风险更高(风险比1.4 [95%CI 1.1-1.8];P<0.01)。
  • 术后新发心房颤动387例(21%);儿童患者中位随访13年,343例中26例(16%)发生心衰复合结局,尽管96%无复发性左室流出道梗阻。

临床怎么用

  • 在经验丰富的多学科HCM中心,室间隔减容术可有效缓解流出道梗阻,围术期死亡率低。
  • 术后需长期监测心衰发生,尤其对高龄、女性及儿童期接受手术的患者。
  • 术后新发心房颤动常见,应予以关注和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction <35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome. RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient <50 mm Hg at 1 year. After 6.8 years (range, 3.4-9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1-1.3]; P<0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1-1.2] per 5-year increase; P<0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1-1.8]; P<0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction. CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Maurizi N, Antiochos P, Owens A, et al. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation. 2024. PMID: 39355918. doi:10.1161/CIRCULATIONAHA.124.069378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。